Labiotech.eu

News and Trends 7 Jul 2023

FDA approves Alzheimer’s treatment

Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use. The decision makes LEQEMBI the first and only approved treatment shown to reduce the rate of disease progression […]

July 7, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 7 Jul 2023

Swedish researchers look to peptides to destroy viruses

A new study from Sweden shows how a type of peptide from a lactic acid bacterium destroys viruses, including coronavirus. The findings have resulted in a Swedish patent, with an international patent pending. “We’re hoping for a quick turnaround to allow this discovery to be utilised in antiviral treatments and as a complement to vaccine,” […]

July 7, 2023 - 3 minutesmins - By Jim Cornall

In Depth 6 Jul 2023

The biggest private biotech investments in June 2023

The companies Upstream Bio, Alkeus Pharmaceuticals and Worg Pharmaceuticals bagged the biggest biotech investments in June 2023, with oncology and ophthalmology players in particular attracting the most funding rounds. Overall, more funding rounds took place in June 2023 than in May, and the U.S. healthcare sector once again attracted particularly big rounds. We’ve gathered the […]

July 6, 2023 - 2 minutesmins - By Willow Shah-Neville

News and Trends 6 Jul 2023

LIfT produces neutrophil-based cell therapy from iPSCs

LIfT BioSciences has announced successful proof-of-concept production of its patented cancer-killing alpha neutrophils from induced pluripotent stem cells (iPSCs). The proof-of-concept using iN-LIfT, the company’s second-generation platform, which is derived from iPSCs (a type of cell that has been reprogrammed so it is capable of becoming any type of cell) has shown that the alpha […]

July 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 6 Jul 2023

Positive data from Sensorion hearing loss study

Sensorion, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has reported further analysis from its Proof of Concept (POC) phase 2a clinical trial of SENS-401 for residual hearing preservation in adult patients following cochlear implantation. In June 19, Sensorion announced that in preliminary […]

July 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 6 Jul 2023

AstraZeneca non-small cell lung cancer drug meets primary endpoint

Positive high-level results from AstraZeneca’s TROPION-Lung01 phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy. […]

July 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 6 Jul 2023

£100M LifeArc program aims to help people living with rare diseases

LifeArc, a self-funded, non-profit medical research organization and charity, is launching a new program to invest more than £100 million ($127.2 million) by 2030 to deliver new breakthroughs to improve the lives of people living with a rare disease. The Rare Disease Translational Challenge will bring together researchers in rare disease with LifeArc to get […]

July 6, 2023 - 4 minutesmins - By Jim Cornall

Best in Biotech 5 Jul 2023

Six biotech companies leading the way in Hong Kong

With a land area of 1,108 square kilometers, Hong Kong is one of the smallest countries in Asia. The country, which is dependent on international trade and finance, has a healthcare market that is projected to hit $67.26 million this year. The country, which is home to over 250 biopharma companies, is a popular initial […]

July 5, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 5 Jul 2023

Narcolepsy drug gets Chinese approval

RareStone Group, a rare disease-focused company aiming to establish the first rare disease ecosystem in China, has announced that the Chinese National Medical Products Administration (NMPA) has approved pitolisant (Wakix) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. In China, pitolisant is the first approved innovative drug for […]

July 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 Jul 2023

Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment

Innovent Biologics, Inc. and IASO Biotechnology have announced that China’s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO (Equecabtagene Autoleucel). FUCASO is the first fully-human BCMA-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior […]

July 4, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 4 Jul 2023

Camena Bioscience raises $10M for DNA synthesis platform

Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, has closed a $10m Series A financing round, led by Mercia. The new funding will be used to scale operations and continue development of its DNA synthesis platform, gSynth. Camena Bioscience is the first company to offer the enzyme-based DNA synthesis […]

July 4, 2023 - 2 minutesmins - By Jim Cornall

Cristina Müller heads the Nuclide Chemistry research group at the Paul Scherrer Institute.

News and Trends 4 Jul 2023

New drug helps prostate cancer patients

Researchers at the Paul Scherrer Institute (PSI) in Switzerland have developed a new drug that could increase the survival chances of patients with metastatic prostate cancer. The drug is now being tested on patients in the PROGNOSTICS project. A research consortium consisting of the PSI, the University Hospital Basel and ETH Zurich is receiving CHF […]

July 4, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

FDA approves Alzheimer’s treatment

Swedish researchers look to peptides to destroy viruses

The biggest private biotech investments in June 2023

LIfT produces neutrophil-based cell therapy from iPSCs

Positive data from Sensorion hearing loss study

AstraZeneca non-small cell lung cancer drug meets primary endpoint

£100M LifeArc program aims to help people living with rare diseases

Six biotech companies leading the way in Hong Kong

Narcolepsy drug gets Chinese approval

Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment

Camena Bioscience raises $10M for DNA synthesis platform

New drug helps prostate cancer patients

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!